J Thorac Cardiovasc Surg 2007;134:1053-1054
© 2007 The American Association for Thoracic Surgery
Fatal thrombosis in complex cardiac surgery without deep hypothermic circulatory arrest in the setting of standard-of-care heparinization: Status quo and directions for further research
John G.T. Augoustides, MD, FASE*
Cardiothoracic Section, Anesthesiology and Critical Care, Hospital of the University of Philadelphia, Philadelphia, Pa.
Received for publication June 6, 2007; accepted for publication June 21, 2007.
* Address for reprints: John G. T. Augoustides, MD, FASE, Assistant Professor, Cardiothoracic Section, Anesthesiology and Critical Care, Dulles 680, Hospital of the University of Philadelphia, 3400 Spruce St, Philadelphia, PA 19104-4283. (Email: yiandoc{at}hotmail.com).
Fatal thrombosis in complex cardiac surgery without deep hypothermic circulatory arrest was highlighted in a case report of biventricular assist device placement complicated by aortic cannula thrombosis and subsequent fatal cerebral infarction.1
The risk factors identified in this case were aprotinin exposure and stasis of blood in the aortic cannula after protamine administration. Despite standard-of-care heparinization, this syndrome has persisted, as evidenced by a series of case reports (n = 4: 1996-2006).1-4 The purpose of this brief communication is to review this cumulative case series to guide further investigation. The literature search was conducted with PubMed (last entry May 31, 2007) with the following search terms: thrombosis and cardiac surgery; aprotinin and thrombosis in cardiac surgery; aminocaproic acid and thrombosis in cardiac surgery; tranexamic acid and thrombosis in cardiac surgery; and factor VIII and thrombosis in cardiac surgery. One case report was excluded inasmuch as it was later included as part of a larger case series.3
As a group, the published case reports of fatal thrombosis in complex cardiac surgery without deep hypothermic circulatory arrest can be summarized as follows1-4:
- 1 The cohort total is 12 patients (7 men; 5 women).
- 2 The age range is 19 to 69 years.
- 3 All patients had antifibrinolytic therapy (11 aprotinin; 1 aminocaproic acid).
- 4 Anticoagulation was with bolus heparin titrated to maintain the activated clotting time (ACT) greater than 500 seconds (10 kaolin-based ACT; 1 celite-based ACT; 1 unspecified activator).
- 5 The type of complex cardiac surgery was as follows: valve replacement for infective endocarditis in 2 patients; ventricular assist device implantation in 6 patients; heart transplantation in 2 patients; and left ventricular reconstruction with a mitral valve procedure in 2 patients.
- 6 In 11 of 12 patients, circulatory collapse resulting from intravascular thrombosis began within 60 minutes of separation from cardiopulmonary bypass and protamine administration. In the remaining patient, gross thrombus was seen in the aortic cannula and ascending aorta within 60 minutes of protamine administration.
- 7 The circulatory collapse was in all cases severe, requiring reheparinization and return to cardiopulmonary bypass. The predominant hemodynamic pattern was right ventricular failure with acute pulmonary hypertension (10/11 cases).
- 8 The degree of thrombosis in all cases was clinically significant and all cardiovascular compartments were at risk: venous, arterial, capillary, and cardiac chambers. In 3 of 12 patients, the thrombus formation was evident on visual inspection. In 9 of 12, autopsy demonstrated diffuse microthrombi.
- 9 Fibrinolysis with tissue plasminogen activator was used as emergency rescue therapy in 2 patients. In 1 patient, this resulted in clinical improvement that allowed transfer to the intensive care unit. Unfortunately, this patient died subsequently of massive bleeding.
- 10 The syndrome has a 100% mortality.
- 11 In 1 patient, antibodies were detected that activated platelets via Fc-receptor IIa. In 11 of 12 patients, investigation for coagulation abnormalities was not reported.
This case series is limited by the small sample size and suggests more questions than answers. Despite these limitations, the following observations may serve to direct future study of this fatal syndrome:
- 1 A global case registry would boost sample size and thus facilitate further analysis.
- 2 Preoperative hypercoagulable states may participate in the pathophysiology of the syndrome.
- 3 In the presence of an antifibrinolytic, standard-of-care heparinization for complex cardiac surgery in adults does not protect all patients from serious intraoperative thrombotic complications.
- 4 To date, this syndrome has not been reported in association with tranexamic acid or recombinant factor VIII.5
- 5 When a case occurs, the index patient and family should be investigated for concomitant hypercoagulable states.
Despite the advances in complex cardiac surgery without deep hypothermic circulatory arrest, there are still patients at risk for lethal vascular thrombosis. Further investigation is a priority to delineate the pathogenesis and effective therapy for this rare but important syndrome.
References
- Gitter R, Alivizianos P, Capehart J, Ramsay M, Jett GK. Aprotinin and aortic cannula thrombosis. J Thorac Cardiovasc Surg 1996;112:537-538.[Free Full Text]
- Augoustides JG, Kilbaugh T, Harris H, Glick JH, Acker M, Savino JS. Fatal thrombosis after mitral valve replacement for endocarditis: aprotinin and disseminated intravascular coagulation. Anesthesiology 2006;104:213.[Medline]
- Cooper JR, Abrams J, Frazier OH, Radovancevic R, Radovancevic B, Bracey AW, et al. Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy. J Thorac Cardiovasc Surg 2006;131:963-968.[Abstract/Free Full Text]
- Kottenberg-Assenmacher E, Volbracht L, Jakob H, Greinacher A, Peters J. Disseminated intravascular clotting associated with Fc-receptor IIa–mediated platelet activation in a patient with endocarditis after aortic valve replacement. Br J Anaesth 2006;97:630-633.[Abstract/Free Full Text]
- Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-2311.[Medline]
